Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YB-01
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
YB-01 is a therapeutic cancer vaccine targeting Mucin 1 (MUC1), currently under development by Peking Union Medical College Hospital for the treatment of advanced solid tumors. MUC1 is a transmembrane glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial cancers, including breast, lung, and gastrointestinal tumors. The vaccine is designed to stimulate the patient's immune system to recognize and mount a cytotoxic T-lymphocyte response against MUC1-expressing malignant cells. YB-01 is being evaluated in clinical trials, including dose-escalation studies, to determine its safety, tolerability, and preliminary efficacy in patients with advanced malignancies that have failed standard therapies.
- Other names
- MUC1 therapeutic tumor vaccineMUC-1 therapeutic tumor vaccineMUC 1 therapeutic tumor vaccineYB-01 MUC1 vaccineYB01 MUC1 vaccineYB 01 MUC1 vaccine
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on YB-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YB-01.